Stockreport

Novo Nordisk hopes to launch experimental obesity drug this decade [Reuters]

Catalent, Inc.  (CTLT) 
Last catalent, inc. earnings: 2/3 07:30 am Check Earnings Report
US:NYSE Investor Relations: investor.catalent.com
PDF the drugmaker would be able to launch the pill version of its experimental weight loss drug amycretin this decade. Below are the highlights of interviews with Martin L [Read more]